Gebre Melat, Woodbury Anna, Napadow Vitaly, Krishnamurthy Venkatagiri, Krishnamurthy Lisa C, Sniecinski Roman, Crosson Bruce
Center for Visual and Neurocognitive Rehabilitation, Research & Development, Atlanta Veterans Affairs Medical Center, Decatur, GA, United States.
Division of Pain Medicine, Department of Anesthesiology, Emory University School of Medicine, Atlanta, GA, United States.
JMIR Res Protoc. 2018 Feb 6;7(2):e39. doi: 10.2196/resprot.8692.
Fibromyalgia is a chronic pain state that includes widespread musculoskeletal pain, fatigue, psychiatric symptoms, cognitive and sleep disturbances, and multiple somatic symptoms. Current therapies are often insufficient or come with significant risks, and while there is an increasing demand for non-pharmacologic and especially non-opioid pain management such as that offered through complementary and alternative medicine therapies, there is currently insufficient evidence to recommend these therapies. Percutaneous electrical neural stimulation (PENS) is an evidence-based treatment option for pain conditions that involves electrical current stimulation through needles inserted into the skin. Percutaneous electrical neural field stimulation (PENFS) of the auricle is similar to PENS, but instead of targeting a single neurovascular bundle, PENFS stimulates the entire ear, covering all auricular branches of the cranial nerves, including the vagus nerve. The neural mechanisms of PENFS for fibromyalgia symptom relief are unknown.
We hypothesize that PENFS treatment will decrease functional brain connectivity between the default mode network (DMN) and right posterior insula in fibromyalgia patients. We expect that the decrease in functional connectivity between the DMN and insula will correlate with patient-reported analgesic improvements as indicated by the Defense and Veterans Pain Rating Scale (DVPRS) and will be anti-correlated with patient-reported analgesic medication consumption. Exploratory analyses will be performed for further hypothesis generation.
A total of 20 adults from the Atlanta Veterans Affairs Medical Center diagnosed with fibromyalgia will be randomized into 2 groups: 10 subjects to a control (standard therapy) group and 10 subjects to a PENFS treatment group. The pragmatic, standard therapy group will include pharmacologic treatments such as anticonvulsants, non-steroidal anti-inflammatory drugs, topical agents and physical therapy individualized to patient comorbidities and preferences, prescribed by a pain management practitioner. The PENFS group will include the above therapies in addition to the PENFS treatments. The PENFS subject group will have the Neuro-Stim System placed on the ear for 5 days then removed and replaced once per week for 4 weeks. The primary outcome will be resting functional magnetic resonance imaging connectivity between DMN and insula, which will also be correlated with pain relief and functional improvements. This connectivity will be analyzed utilizing functional connectivity magnetic resonance imaging (fcMRI) and will be compared with patient-reported analgesic improvements as indicated by the DVPRS and patient-reported analgesic medication consumption. Pain and function will be further evaluated using Patient-Reported Outcomes Measurement Information System measures and measures describing a person's functional status from Activity and Participation section of the International Classification of Functioning Disability and Health.
This trial has been funded by the Veterans Health Administration Program Office. This study attained approval by the Emory University/Veterans Affairs (VA) institutional review board and VA Research & Development committee. Institutional review board expedited approval was granted on 2/7/17 (IRB00092224). The study start date is 6/1/17 and estimated completion date is 5/31/20. The recruitment started in June 2017.
This is a feasibility study that is meant to demonstrate the practicality of using fcMRI to study the neural correlates of PENFS outcomes and provide information regarding power calculations in order to design and execute a larger randomized controlled clinical trial to determine the efficacy of PENFS for improving pain and function.
ClinicalTrials.gov NCT03008837; https://clinicaltrials.gov/ct2/show/NCT03008837 (Archived by WebCite at http://www.webcitation.org/6wrY3NmaQ).
纤维肌痛是一种慢性疼痛状态,包括广泛的肌肉骨骼疼痛、疲劳、精神症状、认知和睡眠障碍以及多种躯体症状。目前的治疗方法往往效果不佳或存在重大风险,虽然对非药物尤其是非阿片类疼痛管理的需求不断增加,如通过补充和替代医学疗法提供的管理,但目前尚无足够证据推荐这些疗法。经皮电神经刺激(PENS)是一种针对疼痛病症的循证治疗选择,它通过插入皮肤的针进行电流刺激。耳廓经皮电场刺激(PENFS)与PENS类似,但PENFS不是针对单个神经血管束,而是刺激整个耳朵,覆盖颅神经的所有耳廓分支,包括迷走神经。PENFS缓解纤维肌痛症状的神经机制尚不清楚。
我们假设PENFS治疗将降低纤维肌痛患者默认模式网络(DMN)与右侧后岛叶之间的功能性脑连接。我们预计,DMN与岛叶之间功能连接的降低将与患者报告的镇痛改善相关,如国防和退伍军人疼痛评定量表(DVPRS)所示,并且将与患者报告的镇痛药物消耗呈负相关。将进行探索性分析以进一步生成假设。
共有20名来自亚特兰大退伍军人事务医疗中心被诊断为纤维肌痛的成年人将被随机分为2组:10名受试者进入对照组(标准治疗),10名受试者进入PENFS治疗组。务实的标准治疗组将包括抗惊厥药、非甾体抗炎药、局部用药等药物治疗以及根据患者合并症和偏好个体化的物理治疗,由疼痛管理从业者开出处方。PENFS组除了上述治疗外还将包括PENFS治疗。PENFS受试者组将在耳朵上放置神经刺激系统5天,然后取下,每周更换一次,共4周。主要结局将是DMN与岛叶之间的静息功能磁共振成像连接,这也将与疼痛缓解和功能改善相关。这种连接将利用功能连接磁共振成像(fcMRI)进行分析,并将与DVPRS所示的患者报告的镇痛改善以及患者报告的镇痛药物消耗进行比较。疼痛和功能将使用患者报告结局测量信息系统的测量方法以及从《国际功能、残疾和健康分类》活动和参与部分描述一个人功能状态的测量方法进行进一步评估。
该试验由退伍军人健康管理局项目办公室资助。本研究获得了埃默里大学/退伍军人事务部(VA)机构审查委员会和VA研发委员会的批准。机构审查委员会于2017年2月7日给予快速批准(IRB00092224)。研究开始日期为2017年6月1日,预计完成日期为2020年5月31日。招募工作于2017年6月开始。
这是一项可行性研究,旨在证明使用fcMRI研究PENFS结果的神经相关性的实用性,并提供有关功效计算的信息,以便设计和实施一项更大的随机对照临床试验,以确定PENFS改善疼痛和功能的疗效。
ClinicalTrials.gov NCT03008837;https://clinicaltrials.gov/ct2/show/NCT03008837(由WebCite存档于http://www.webcitation.org/6wrY3NmaQ)。